Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.6.0.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Dec. 31, 2015
Current Assets    
Cash and cash equivalents $ 19,055 $ 20,818
Prepaid expenses and other current assets 2,515 9,519
Total Current Assets 21,570 30,337
Property and equipment, net 905 494
Deposits and other assets 23 14
Total Assets 22,498 30,845
Current Liabilities:    
Accounts payable 1,993 4,413
Accrued expenses 2,627 297
Warrant liabilities 14,821 10,567
Accrued employee benefits 313 277
Deferred rent 3 21
Total Current Liabilities 19,757 15,575
Long term deferred rent 492 267
Total Liabilities 20,249 15,842
Commitments and Contingencies 0 0
Stockholders' Equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 250,000,000 shares authorized, 117,254,196 issued and 117,172,714 outstanding and 90,908,234 issued and 90,826,752 outstanding, respectively 117 91
Additional paid-in capital 175,762 160,739
Accumulated deficit (172,034) (144,779)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 3,845 16,051
Non-controlling interest (1,596) (1,048)
Total Stockholders' Equity 2,249 15,003
Total Liabilities and Stockholders' Equity $ 22,498 $ 30,845